UBE2T and endometrial cancer: In summary, increased expression of UBE2T in endometrial cancer tissues may suppress the anti-tumor immune response in UCEC patients, participating in various biological processes such as tumor initiation, metastasis, and invasion, and correlating with poorer survival rates.